PHANTOMICS (CEO Kim Pan-gi) announced that it will participate in CES 2024, which will be held in Las Vegas, USA from Tuesday, January 9 to January 12 (Friday, local time) next year.
PHANTOMICS is a bio startup that possesses imaging biomarker technology that provides quick and accurate diagnostic results through medical images such as MRI and CT. Based on this technology, the company introduced Myomics, a myocardial disease diagnosis solution. Pantomics continues research and development to expand the scope of rapid and accurate non-invasive diagnostic solutions to cardiovascular, liver, and sarcopenic diseases and to advance technology.
Myomics is used in domestic high-level general hospitals and in Japan, China, Taiwan, and Singapore, and has obtained approval from the U.S. Food and Drug Administration (FDA) and the Korean Ministry of Food and Drug Safety. In addition, we have completed sales contracts with medical device distributors in Southeast Asia and South America, and are in the process of obtaining medical device approvals locally. We expect to generate sales in the first half of next year along with securing overseas licenses.
An official from Pantomics said, “The number one cause of death for the world’s population is heart disease. It is very important to accurately diagnose heart disease and evaluate treatment response. “In many heart diseases, myocardial biopsy, which involves inserting a catheter into the heart to collect myocardial tissue, is essential for accurate diagnosis and monitoring,” he said. “Myomics-virtual biopsy is a safe, rapid, and accurate alternative to this risky and expensive myocardial biopsy.” “It is an invasive artificial intelligence diagnostic solution,” he explained.
Non-invasive diagnosis is a method of diagnosis without making a hole or incision in the body, and representative non-invasive diagnosis technologies include X-rays (X-rays), magnetic resonance imaging (MRI), and computed tomography (CT). It is painless and comfortable compared to invasive methods that inevitably cause damage to the body, but is less accurate than invasive diagnosis. However, it is known that the scope and accuracy of non-invasive diagnosis are improving recently due to technological advancements. PHANTOMICS launched Myomics in early 2022 and emphasized that it extracts dozens of image biomarkers non-invasively using cardiac MRI, thereby safely and accurately diagnosing myocardial diseases such as heart failure, myocarditis, and amyloidosis. did.
Regarding the solution, an official said, “We developed an optimal model using the best artificial intelligence algorithm and improved diagnostic accuracy by performing optimization based on local data. “In addition, we have implemented a sophisticated algorithm that allows continuous updating of all clinical evidence published until recently.”
In addition, its features include an explanation function optimized for doctors, nurses, patients, and guardians, a workflow that approaches from presenting key evidence, and the ability to be used in all systems including hospital information system, web, and mobile. In terms of technology, it is possible to maintain diagnostic accuracy while maintaining zero harm (risk) to patients and automating the diagnostic process that required expert intervention. As results accumulate, diagnostic accuracy can evolve based on data, based on data standardization. The advantage is that patients can be treated with the same information anywhere in the world because information is compatible.
In 2024, Pantomics plans to launch ▲Hepatomics solution, software with automatic liver disease MRI analysis function, ▲Angiomics solution, automatic coronary artery CT analysis function software, and ▲Sacromics solution, automatic analysis function software for CT for sarcopenia and low-muscle type obesity.
Meanwhile, ‘CES’, the world’s largest IT exhibition hosted by the Consumer Technology Association (CTA), is an exhibition where you can see the flow of innovative technologies around the world at a glance and is held every January in Las Vegas, USA. AVING News, which has covered CES for 18 consecutive years, has reported CES news around the world every year since 2006, and has been selected through ‘BEST OF CES’ and ‘BEST OF MADE IN KOREA’, which select the best innovative products, companies and technologies. has been in progress. In addition, CES on-site issues are vividly conveyed through ‘AVING LIVE’.
The CES 2024 Seoul Unified Hall will be operated at the largest scale in terms of exhibition area, number of participating companies, and number of participating supporters since Seoul City’s first participation in CES in 2020. The Seoul Integration Center, in which 13 organizations collaborate and participate, is an important step in Seoul’s efforts to make Seoul a mecca for startups, and 17 of the companies participating in the Seoul Integration Center proved this by receiving innovation awards. The participating institutions in the Seoul Unification Center are ▲SBA ▲Seoul Bio Hub ▲Campus Town ▲AI Yangjae Hub ▲Gwanak-gu ▲Yonsei University ▲Korea University ▲Chung-Ang University ▲Sogang University ▲Kookmin University ▲Hanyang University ▲Konkuk University ▲Kyunghee University. Not only the Seoul Metropolitan Government, institutions, and companies, but also supporters through industry-academia cooperation are matched 1:1 with companies, and 85 supporters, the largest number, will participate.
* Special reporters: Joseph Choe, Kidai Kim, Dongkwan Kim, Mokkyung Lee, Sangun Choi, Seung Hyun Nam, Sunghwan Kim, Taeuck Lim, Min Choi
→ Go to the CES 2024 news special page